Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tdap vaccine recommendations

Executive Summary

Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices recommends routine Tdap (tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed) vaccination of adolescents ages 11-12 years. Panel also recommends catch-up program for adolescents who have already received Td booster. FDA recently approved two Tdap vaccines: GlaxoSmithKline's Boostrix and Sanofi-Aventis' Adacel (1"The Pink Sheet" June 20, 2005, p. 28)...

You may also be interested in...



Sanofi’s Adacel Tdap Vaccine Receives Broader Approval Than GSK’s Boostrix

Sanofi-Aventis' postmarketing commitments for Adacel include a 16,000-patient epidemiologic safety surveillance study of the tetanus, diphtheria and acellular pertussis vaccine

Zydus Cadila Testing Three-Dose COVID-19 Vaccine

Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.

Six Questions For Sun Pharma MD Shanghvi

Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel